White blood cell count predicts response to lung cancer immunotherapy

White blood cell counts can predict whether or not lung cancer patients will benefit from immunotherapy, according to research presented at the European Lung Cancer Conference (ELCC). “Immune checkpoint inhibitors such as nivolumab and pembrolizumab significantly improve overall survival in some — but not all — patients with non-small cell lung cancer (NSCLC),” said lead author Dr Marcello Tiseo, Coordinator of DMT Thoracic Oncology, University Hospital of Parma, Italy. “Researchers are looking for a predictive biomarker to select patients that will benefit from this treatment to avoid unnecessary toxicity and a waste of resources in patients who will not respond.”…
View More/Source Article
Featured on Healthpages.wiki
Specialised in diagnosis and management of Lung Cancer, Asthma, Emphysema, Sleep disordered breathing, Chronic Cough, Sarcoidosis, Pleural disease and other respiratory conditions. Special interest is pulmonary intervention.